"Two-route chemotherapy" using high-dose intra-arterial neocarzinostatin and systemic tiopronin, its antidote, for rat limb tumor.
We studied the effect of "two-route chemotherapy" (TRC) with intra-arterial (IA) neocarzinostatin (NCS) and IV N-(2-mercaptopropionyl)-glycine (tiopronin), its antidote, on rat limb tumors. Chemotherapy experiments were carried out on day 9 after the inoculation of 10(6) syngeneic transitional carcinoma cells into the hind limb in female Wistar King A rats. In the group given TRC, 3500 units/kg NCS and 800 mg/kg tiopronin were given via the femoral artery and the femoral vein, respectively. The antitumor effect was evaluated by the tumor weight on day 12 after the treatment. Compared with the weight of tumors in untreated controls, TRC reduced tumor weight to one-tenth, while 700 units/kg IA NCS alone reduced tumor weight to one-third and 700 units/kg systemic NCS alone reduced tumor weight to three-fourths of the control weight. In the group given TRC, WBC and nucleated bone marrow cells were completely protected and loss of body weight was slight.
D000818:Animals; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage*; D001835:Body Weight / Q000187:drug effects; D001853:Bone Marrow / Q000378:metabolism; D002295:Carcinoma, Transitional Cell / Q000188:drug therapy*; D005260:Female; D007261:Infusions, Intra-Arterial; D007263:Infusions, Parenteral; D007962:Leukocytes / Q000187:drug effects; D051379:Mice; D008815:Mice, Inbred Strains; D051381:Rats; D011919:Rats, Inbred Strains; D008625:Tiopronin / Q000008:administration & dosage; D009353:Zinostatin / Q000008:administration & dosage / Q000633:toxicity
D009353:Zinostatin; D008625:Tiopronin